Acute myeloid leukemia (AML) is often characterized by the expression of fusion or mutant proteins that cause impaired differentiation and enhanced proliferation and survival. The presence of mutant proteins prone to misfolding can render the cells sensitive to endoplasmic reticulum (ER) stress and oxidative stress that could otherwise be overcome. Here, we show that the triple combination of the differentiating agent retinoic acid (RA), the ER stress-inducing drug tunicamycin (Tm), and arsenic trioxide (ATO), able to generate oxidative stress, leads to the death of AML cell lines expressing fusion proteins involving the gene MLL and the internal tandem duplication (ITD) in the FLT3 tyrosine kinase receptor. Importantly, the combination of RA, Tm, and ATO decreased the colony-forming capacity of primary leukemic blasts bearing the FLT-ITD mutation without affecting healthy hematopoietic progenitor cells. We demonstrate in cell lines that combination of these drugs generates ER and oxidative stresses and impairs maturation and causes accumulation of FLT3 protein in the ER. Our data provide a proof of concept that low amounts of drugs that generate ER and oxidative stresses combined with RA could be an effective targeted therapy to hit AML cells characterized by MLL fusion proteins and FLT3-ITD mutation.

Retinoic acid synergizes with the unfolded protein response and oxidative stress to induce cell death in FLT3-ITD+ AML / Masciarelli, Silvia; Capuano, Ernestina; Ottone, Tiziana; Divona, Mariadomenica; Lavorgna, Serena; Liccardo, Francesca; Śniegocka, Martyna; Travaglini, Serena; Noguera, Nelida I; Picardi, Alessandra; Petrozza, Vincenzo; Fatica, Alessandro; Tamagnone, Luca; Voso, Maria Teresa; Lo Coco, Francesco; Fazi, Francesco. - In: BLOOD ADVANCES. - ISSN 2473-9529. - 3:24(2019), pp. 4155-4160. [10.1182/bloodadvances.2019000540]

Retinoic acid synergizes with the unfolded protein response and oxidative stress to induce cell death in FLT3-ITD+ AML

Masciarelli, Silvia;Capuano, Ernestina;LICCARDO, FRANCESCA;Śniegocka, Martyna;Petrozza, Vincenzo;Fatica, Alessandro;Fazi, Francesco
2019

Abstract

Acute myeloid leukemia (AML) is often characterized by the expression of fusion or mutant proteins that cause impaired differentiation and enhanced proliferation and survival. The presence of mutant proteins prone to misfolding can render the cells sensitive to endoplasmic reticulum (ER) stress and oxidative stress that could otherwise be overcome. Here, we show that the triple combination of the differentiating agent retinoic acid (RA), the ER stress-inducing drug tunicamycin (Tm), and arsenic trioxide (ATO), able to generate oxidative stress, leads to the death of AML cell lines expressing fusion proteins involving the gene MLL and the internal tandem duplication (ITD) in the FLT3 tyrosine kinase receptor. Importantly, the combination of RA, Tm, and ATO decreased the colony-forming capacity of primary leukemic blasts bearing the FLT-ITD mutation without affecting healthy hematopoietic progenitor cells. We demonstrate in cell lines that combination of these drugs generates ER and oxidative stresses and impairs maturation and causes accumulation of FLT3 protein in the ER. Our data provide a proof of concept that low amounts of drugs that generate ER and oxidative stresses combined with RA could be an effective targeted therapy to hit AML cells characterized by MLL fusion proteins and FLT3-ITD mutation.
2019
myeloid differentiation; ER stress; cell death; myeloid leukemia
01 Pubblicazione su rivista::01a Articolo in rivista
Retinoic acid synergizes with the unfolded protein response and oxidative stress to induce cell death in FLT3-ITD+ AML / Masciarelli, Silvia; Capuano, Ernestina; Ottone, Tiziana; Divona, Mariadomenica; Lavorgna, Serena; Liccardo, Francesca; Śniegocka, Martyna; Travaglini, Serena; Noguera, Nelida I; Picardi, Alessandra; Petrozza, Vincenzo; Fatica, Alessandro; Tamagnone, Luca; Voso, Maria Teresa; Lo Coco, Francesco; Fazi, Francesco. - In: BLOOD ADVANCES. - ISSN 2473-9529. - 3:24(2019), pp. 4155-4160. [10.1182/bloodadvances.2019000540]
File allegati a questo prodotto
File Dimensione Formato  
Masciarelli_Retinoic_2019.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 1.15 MB
Formato Adobe PDF
1.15 MB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1348145
Citazioni
  • ???jsp.display-item.citation.pmc??? 9
  • Scopus 24
  • ???jsp.display-item.citation.isi??? 23
social impact